The 27 references in paper A. Kolbin S., I. Vilum A., М. Proskurin A., Yu. Balykina E., А. Колбин С., И. Вилюм А., М. Проскурин А., Ю. Балыкина Е. (2017) “ФАРМАКОЭКОНОМИЧЕСКИЙ АНАЛИЗ ПРИМЕНЕНИЯ БРЕНТУКСИМАБА ВЕДОТИНА В ТЕРАПИИ РЕЦИДИВИРУЮЩЕЙ ИЛИ РЕФРАКТЕРНОЙ CD30+ СИСТЕМНОЙ АНАПЛАСТИЧЕСКОЙ КРУПНОКЛЕТОЧНОЙ ЛИМФОМЫ У ПАЦИЕНТОВ СТАРШЕ 18 ЛЕТ: РЕЗУЛЬТАТЫ АНАЛИЗА ВЛИЯНИЯ НА БЮДЖЕТ ЗДРАВООХРАНЕНИЯ // PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS” / spz:neicon:pharmacoeconomics:y:2017:i:1:p:39-45

1
Russian clinical recommendations on diagnostics and treatment of lymphoproliferative disorders. Under the guidance of Professor I. V. Poddubnaya, Professor V. G. Savchenko [Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniyu limfoproliferativnykh zabolevanii. Pod rukovodstvom prof. I. V. Poddubnoi, prof. V. G. Savchenko (in Russian)]. Moscow. 2016; 324 s.
(check this in PDF content)
2
Jacobsen e. Anaplastic large-cell lymphoma, T-null-cell type. Oncologist. 2006; 11: 831-840.
(check this in PDF content)
3
Tilly h., Gaulard P., Lepage e., et al. Primary anaplastic largecell lymphoma in adults: Clinical presentation, immunophenotype, and outcome. Blood. 1997; 90: 3727-3734.
(check this in PDF content)
4
Savage K. J., harris N. L., Vose J. M., et al. ALK-anaplastic largecell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008; 111: 5496-5504.
(check this in PDF content)
5
hapgood G., Savage K. J.X. Challenges and future directions in peripheral T-cell lymphoma. hematol Oncol. 2015; 33 (1): 56-61.
(check this in PDF content)
6
Russian clinical recommendations on diagnostics and treatment of lymphoproliferative disorders. Under the guidance of Professor I. V. Poddubnaya, Professor V. G. Savchenko [Rosciiskie klinicheskie rekomendatsii po diagnostike i lecheniyu limfoproliferativnykh zabolevanii. Pod rukovodstvom prof. I. V. Poddubnoi, prof. V. G. Savchenko (in Russian)]. Moscow. 2014; 128.
(check this in PDF content)
7
Tumyan G. S. Klinicheskaya onkogematolologiya. Fundamental’nye issledovaniya i klinicheskaya praktika. 2015; 8 (4): 455-470.
(check this in PDF content)
8
Rodriguez J., Munsell M., Yazji S., et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol. 2001; 19: 3766-3770.
(check this in PDF content)
9
Moskowitz C. h., Nimer S. D., Glassman J. R., et al. The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant. 1999; 23: 561-567.
(check this in PDF content)
10
Shipp M. A., Abeloff M. D., Antman K. h., et al. International Consensus Conference on high-Dose Therapy with hematopoietic Stem Cell Transplantation in Aggressive Non-hodgkin’s Lymphomas: Report of the jury. J Clin Oncol. 1999; 17: 423-429.
(check this in PDF content)
11
ProB., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30 (18): 2190-6.
(check this in PDF content)
12
Chao-Ming Lai C-M., et al. Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma. Expert Review of hematology. 2013; 6: (4): 361-373.
(check this in PDF content)
13
Fanale M. A., et al. Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30 Peripheral T-Cell Lymphomas: Results of a Phase I Study. J Clin Oncol. 2014; 32: 3137-3143.
(check this in PDF content)
14
Al’-Radi L. S., Baryakh e. A., Belousova I. e., et al. Clinical practice guidelines for the diagnosis and treatment of lymphoproliferative disorders. Association of oncologists of Russia. URL: http://oncology-association.ru/docs/recomend/2016/59klin-rek. pdf. Accessed: 10.12.2016.
(check this in PDF content)
15
Malignant neoplasms in Russia in 2015 (morbidity and mortality). edited by A. D. Kaprina, V. V. Stalinskogo, G. V. Petrova [Zlokachestvennye novoobrazovaniya v Rossii v 2015 godu (zabolevaemost’ i smertnost’). Pod redaktsiei A. D. Kaprina, V. V. Starinskogo, G. V. Petrovoi (in Russian)]. Moscow. 2016.
(check this in PDF content)
16
Guidelines for the assessment of the impact of the budget in the framework of the program of state guarantees of free rendering to citizens of medical aid. Fsbi “ZeCKe” Ministry of health of Russia. Approved by order of the fgbi “ZeCKe” Ministry of health of Russia from 23 December 2016 No 145-od. [Metodicheskie rekomendatsii po otsenke vliyaniya na byudzhet v ramkakh realizatsii programmy gosudarstvennykh garantiĭ besplatnogo okazaniya grazhdanam meditsinskoĭ pomoshchi. FGBU «TsEKKMP» Minzdrava Rossii. Utverzhdeny prikazom FGBU «TsEKKMP» Minzdrava Rossii ot «23» dekabrya 2016 g. No 145-od. (in Russian)]. Moscow. 2016.
(check this in PDF content)
17
Brosa M., Gisbert R., Rodríguez Barrios J.M, Soto J. Principios, métodos y aplicaciones del análisisdel impacto presupuestario en sanidad. Pharmacoeconomics Spanish Research Articles. 2005; 2: 65-79.
(check this in PDF content)
18
Basic concepts in health technology assessment: method. allowance. Under. edited by A. S. Kolbin, Zyryanov S. K., Belousov D. Yu. [Osnovnye ponyatiya v otsenke meditsinskikh tekhnologii: metod. posobie. Pod. red. A. S. Kolbina, S. K. Zyryanova, D. Yu. Belousova (in Russian)]. Moscow. 2013; 42 s.
(check this in PDF content)
19
Forero-Torres A., Leonard J. P., Younes A., et al. A phase II study of SGN-30 (anti-CD30 mAb) in hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J haematol. 2009; 146: 171-179.
(check this in PDF content)
20
NCCN, Guidelines. Version 1.2016.
(check this in PDF content)
21
Assessment of medical care to patients c hodgkin’s Lymphoma and systemic anaplastic large cell lymphoma. The expert Council on healthcare of the Federation Council Committee on social policy [Otsenka sostoyaniya okazaniya meditsinskoi pomoshchi bol’nym c Limfomoi Khodzhkina i sistemnoi anaplasticheskoi krupnokletochnoi limfomoi. Ekspertnyi sovet po zdravookhraneniyu Komiteta Soveta Federatsii po sotsial’noi politike (in Russian)]. Moscow. 2015.
(check this in PDF content)
22
Instructions for use of medicinal product for medical use Adcetris® [Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Adtsetris® (in Russian)].
(check this in PDF content)
23
Resolution of the Government of the Russian Federation from 19.12.2015 g. No1382 “On the Programme of state guarantees of free rendering to citizens of medical aid for 2016” [Postanovlenie Pravitel’stva Rossiiskoi Federatsii ot 19.12.2015 g. No1382 «O Programme gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi na 2016 god» (in Russian)].
(check this in PDF content)
24
The official website of the Russian Federation for posting information about placing orders http://zakupki.gov.ru/epz/main/ public/home.html. Accessed: 10.12.2016.
(check this in PDF content)
25
Kolbin A. S., Vilyum I. A., Proskurin M. A., Balykina Yu. e. Klinicheskaya farmakologiya i terapiya. 2016; 25 (2): 90-96.
(check this in PDF content)
26
Official site of Territorial Fund OMS of St.-Petersburg. http:// www.spboms.ru/. Accessed: 10.12.2016.
(check this in PDF content)
27
On approval of the branch standard “clinico-economic studies. General provisions”: the order No. 163 of the Ministry of health of the Russian Federation of 27.05.2011 http://clinvest.ru/news/item/ otraslevoj-standart-kliniko-ekonomicheskie-issledovaniya-obshiepolozheniya. Accessed: 13.12.2016.
(check this in PDF content)